Baxter Healthcare
Executive Summary
Joint R&D agreement with Somatix Therapy will focus on using gene therapy to develop a treatment for hemophilia, the companies announce Nov. 3. Baxter will have worldwide marketing rights to "non-autologous cells, genetically modified with Somatix's MFG retroviral vector," which Baxter will incorporate into its proprietary membrane device and evaluate in clinical trials. Somatix will receive milestone payments and royalties.